Lilly drug misses Phase III target

Share this article:

Eli Lilly's gastric cancer drug Cryamza failed to hit its primary Phase III liver cancer target.

The Indiana drugmaker announced Wednesday that although the drug did not show a statistically significant gain over placebo for overall survival, results indicated “meaningful improvements” in secondary measures including progression-free survival and overall response rate.

ISI analyst Mark Schoenebaum said in April that a hepatocellular cancer indication could be worth around $200 million in sales.

The drug has orphan status for hepatocellular cancer. Lilly is also exploring the drug's use in other cancers, including non-small cell lung cancer.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.